Analyst Price Targets — ACIU
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 13, 2026 1:05 pm | Lucy Codrington | Jefferies | $7.00 | $3.01 | StreetInsider | Jefferies Reiterates Buy Rating on AC Immune SA (ACIU): '2025 financials largely immaterial' |
| May 30, 2024 4:49 pm | Thomas Shrader | BTIG | $8.00 | $3.97 | TheFly | AC Immune initiated with a Buy at BTIG |
| July 11, 2022 6:52 am | — | Leerink Partners | $10.00 | $3.35 | Benzinga | SVB Leerink Maintains Outperform on AC Immune, Lowers Price Target to $10 |
Latest News for ACIU
AC Immune announced positive interim Phase 1 results from a first-in-human clinical study evaluating ACI-19764, an NLRP3 inhibitor targeting inflammation.
AC Immune (ACIU) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to a loss of $0.25 per share a year ago.
AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-term clinical results anticipated for H2 2026 Phase 2 VacSYn trial of ACI-7104 in Parkinson's disease supported by a $4 million grant from The Vijay and Marie Goradia Charitable…
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC ® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces three presentations at the Alzheimer's Association International Conference® 2026, taking place July 12-15 in London, UK. Across…
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three Alzheimer's disease (AD) cohorts in ABATE Anti-Abeta antibody dose-response demonstrated with antibodies detected at all dose levels in cohorts AD1-3 Ongoing AD4 cohort includes additional adjuvant designed to enhance…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ACIU.
U.S. House Trading
No House trades found for ACIU.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.